The Red Chip Review Initiates Coverage With a Discovery Stock Report On SciClone Pharmaceuticals
PORTLAND, Ore., Oct. 20 /PRNewswire/ -- THE RED CHIP REVIEW has chosen SciClone Pharmaceuticals (Nasdaq: SCLN - news) to join the ranks of nearly 200 small-cap stocks currently followed by the small- and micro-cap research publication.
SciClone Pharmaceuticals is a rarity among biopharmaceutical companies
-- it actually generates revenue from direct product sales, one of about 40 that does among the more than 400 companies in this industry. SciClone is a "virtual business," licensing rather than discovering drugs, which significantly reduces its risk as well as its fixed costs. A strong cash position plus products that have demonstrated positive results in therapy for cancer, hepatitis B, hepatitis C and cystic fibrosis suggest this is a stock to watch. Red Chip Review Analyst, Wayne Lottinville initiates coverage with a "B" rating.
THE RED CHIP REVIEW is the nation's leading source of information on small- and micro-cap stocks, providing in-depth research and analysis through a variety of formats, including a popular bi-weekly publication and several online services.
Typically, companies followed by THE RED CHIP REVIEW are undervalued, and underfollowed. Yet they show exciting promise. Because they're smaller, they're usually more nimble companies, often in the early stages of development. They tend to be fast-growing, produce a new product or service, or in some way have a unique story.
THE RED CHIP REVIEW analysts rate companies ''A'' through ''C'' on the basis of a point system that reflects the following judgements:
-- the stock's potential for price appreciation in the next 12 to
18 months -- the company's balance sheet strength, i.e., cash balances, debt level, and current ratio
-- their evaluation of management's integrity, its openness in sharing information about its performance and strategic plan, and its ability to execute that plan.
Well...got a B...
Let's have some earnings and NEWS!
chris |
